Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 5-year comparative imaging trial with glatiramer acetate versus low or high doses of other disease-modifying therapies in treatment-naive patients with relapsing-remitting multiple sclerosis.

Next Previous
Search
Trial Profile

A 5-year comparative imaging trial with glatiramer acetate versus low or high doses of other disease-modifying therapies in treatment-naive patients with relapsing-remitting multiple sclerosis.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glatiramer acetate (Primary) ; Interferon beta-1a; Interferon beta-1b
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 13 Oct 2011 Planned End Date changed to 1 Dec 2007.
  • 11 Oct 2011 Final results of this 5-year brain MRI study have been published in the Journal of the Neurological Sciences, according to a Teva Neuroscience media release.
  • 22 Apr 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top